Marc Frahm
Stock Analyst at TD Cowen
(0.18)
# 4,472
Out of 5,113 analysts
15
Total ratings
16.67%
Success rate
-20.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Maintains: Buy | $101 → $128 | $101.28 | +26.38% | 4 | Jan 13, 2026 | |
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $4.65 | - | 2 | Jan 8, 2025 | |
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $19.11 | -52.90% | 3 | Aug 6, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $11.78 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $0.60 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $102.30 | - | 1 | Aug 23, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $13.83 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $11.36 | - | 1 | Jun 21, 2021 | |
| BDTX Black Diamond Therapeutics | Initiates: Outperform | n/a | $2.65 | - | 1 | Feb 24, 2020 |
Incyte
Jan 13, 2026
Maintains: Buy
Price Target: $101 → $128
Current: $101.28
Upside: +26.38%
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $4.65
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $19.11
Upside: -52.90%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $11.78
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.60
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $102.30
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.83
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $11.36
Upside: -
Black Diamond Therapeutics
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.65
Upside: -